| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Cellular and Structural Biology and 2 Orthopedics, and 3 Center for Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, Texas
Requests for reprints: Lu-Zhe Sun, Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7762, San Antonio, TX 78229-3900. Phone: 210-567-5746; Fax: 210-567-3803; E-mail: sunl{at}uthscsa.edu.
Transforming growth factor-ß (TGF-ß) signaling has been shown to promote invasion and metastasis in various models of human cancers. In this study, we investigated the efficacy of a TGF-ß type I receptor kinase inhibitor (TßRI-I) to limit early systemic metastases in an orthotopic xenograft model of lung metastasis and in an intracardiac injection model of experimental bone and lung metastasis using human breast carcinoma MDA-MB-435-F-L cells, a highly metastatic variant of human breast cancer MDA-MB-435 cells, expressing the enhanced green fluorescent protein (EGFP). Treatment of the cells with the TßRI-I had no effect on their growth but blocked TGF-ß-stimulated expression of integrin 
vß3 and cell migration in vitro. Systemic administration of the TßRI-I via i.p. injection effectively reduced the number and size of the lung metastasis in both orthotopic xenograft and experimental metastasis models with no effects on primary tumor growth rate compared with controls. TßRI-I treatment also reduced the incidence of widespread early skeletal metastases in the femur, tibia, mandible, and spine detected by whole-body EGFP fluorescence imaging. Tumor burden in femora and tibiae was also reduced after TßRI-I treatment as detected by histomorphometry analysis compared with the placebo controls. Our results indicate for the first time that abrogation of TGF-ß signaling by systemic administration of the TßRI-I can inhibit both early lung and bone metastasis in animal model systems and suggest antimetastatic therapeutic potential of the TßRI-I.(Cancer Res 2006; 66(13): 6714-21)
This article has been cited by other articles:
|
|
 |
|
  L. D. Moore, T. Isayeva, G. P. Siegal, and S. Ponnazhagan Silencing of Transforming Growth Factor-{beta}1 In situ by RNA Interference for Breast Cancer: Implications for Proliferation and Migration In vitro and Metastasis In vivo Clin. Cancer Res., August 1, 2008; 14(15): 4961 - 4970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A Kingsley, P. G J Fournier, J. M Chirgwin, and T. A Guise Molecular Biology of Bone Metastasis Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 443 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Melisi, S. Ishiyama, G. M. Sclabas, J. B. Fleming, Q. Xia, G. Tortora, J. L. Abbruzzese, and P. J. Chiao LY2109761, a novel transforming growth factor {beta} receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol. Cancer Ther., April 1, 2008; 7(4): 829 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ehata, A. Hanyu, M. Hayashi, H. Aburatani, Y. Kato, M. Fujime, M. Saitoh, K. Miyazawa, T. Imamura, and K. Miyazono Transforming Growth Factor-{beta} Promotes Survival of Mammary Carcinoma Cells through Induction of Antiapoptotic Transcription Factor DEC1 Cancer Res., October 15, 2007; 67(20): 9694 - 9703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Kingsley, P. G.J. Fournier, J. M. Chirgwin, and T. A. Guise Molecular Biology of Bone Metastasis Mol. Cancer Ther., October 1, 2007; 6(10): 2609 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G.J. Fournier and T. A. Guise BMP7: A New Bone Metastases Prevention? Am. J. Pathol., September 1, 2007; 171(3): 739 - 743. [Full Text] [PDF]
|
|
|
|
|
|
E. V. Verona, A. G. Elkahloun, J. Yang, A. Bandyopadhyay, I-T. Yeh, and L.-Z. Sun Transforming Growth Factor-{beta} Signaling in Prostate Stromal Cells Supports Prostate Carcinoma Growth by Up-regulating Stromal Genes Related to Tissue Remodeling Cancer Res., June 15, 2007; 67(12): 5737 - 5746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, R. Bachelier, I. Treilleux, P. Pujuguet, O. Peyruchaud, R. Baron, P. Clement-Lacroix, and P. Clezardin Tumor {alpha}v{beta}3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases Cancer Res., June 15, 2007; 67(12): 5821 - 5830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Laping, J. I. Everitt, K. S. Frazier, M. Burgert, M. J. Portis, C. Cadacio, L. I. Gold, and C. L. Walker Tumor-Specific Efficacy of Transforming Growth Factor-{beta}RI Inhibition in Eker Rats Clin. Cancer Res., May 15, 2007; 13(10): 3087 - 3099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Galliher and W. P. Schiemann Src Phosphorylates Tyr284 in TGF-{beta} Type II Receptor and Regulates TGF-{beta} Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion Cancer Res., April 15, 2007; 67(8): 3752 - 3758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Javelaud, K. S. Mohammad, C. R. McKenna, P. Fournier, F. Luciani, M. Niewolna, J. Andre, V. Delmas, L. Larue, T. A. Guise, et al. Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis Cancer Res., March 1, 2007; 67(5): 2317 - 2324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Kano, Y. Bae, C. Iwata, Y. Morishita, M. Yashiro, M. Oka, T. Fujii, A. Komuro, K. Kiyono, M. Kaminishi, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling PNAS, February 27, 2007; 104(9): 3460 - 3465. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
